Qiagen and Molecular Staging, Invitrogen, PhyNexus and Qiagen, and Sprout Group and Sopherion Therapeutics | GenomeWeb

Qiagen Acquires Molecular Staging Assets

Qiagen said this week that it has acquired technology assets from Molecular Staging, including the company’s whole-genome amplification and rolling-circle amplification technologies, for $28.5 million.

Under the terms of the agreement, Qiagen purchased the technology assets of MSI, including more than 160 applied or issued patents, for $28.5 million in cash plus potential earn-outs of up to $6.75 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.